当前位置: 首页 >> 检索结果
4074. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.
作者: Tanya Siddiqi.;David G Maloney.;Saad S Kenderian.;Danielle M Brander.;Kathleen Dorritie.;Jacob Soumerai.;Peter A Riedell.;Nirav N Shah.;Rajneesh Nath.;Bita Fakhri.;Deborah M Stephens.;Shuo Ma.;Tatyana Feldman.;Scott R Solomon.;Stephen J Schuster.;Serena K Perna.;Sherilyn A Tuazon.;San-San Ou.;Eniko Papp.;Leanne Peiser.;Yizhe Chen.;William G Wierda.
来源: Lancet. 2023年402卷10402期641-654页
Patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma for whom treatment has failed with both Bruton tyrosine kinase (BTK) inhibitor and venetoclax have few treatment options and poor outcomes. We aimed to evaluate the efficacy and safety of lisocabtagene maraleucel (liso-cel) at the recommended phase 2 dose in patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma.
4076. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.
作者: Sumanta Kumar Pal.;Laurence Albiges.;Piotr Tomczak.;Cristina Suárez.;Martin H Voss.;Guillermo de Velasco.;Jad Chahoud.;Anastasia Mochalova.;Giuseppe Procopio.;Hakim Mahammedi.;Friedemann Zengerling.;Chan Kim.;Takahiro Osawa.;Martín Angel.;Suyasha Gupta.;Omara Khan.;Guillaume Bergthold.;Bo Liu.;Melania Kalaitzidou.;Mahrukh Huseni.;Christian Scheffold.;Thomas Powles.;Toni K Choueiri.
来源: Lancet. 2023年402卷10397期185-195页
Immune checkpoint inhibitors are the standard of care for first-line treatment of patients with metastatic renal cell carcinoma, yet optimised treatment of patients whose disease progresses after these therapies is unknown. The aim of this study was to determine whether adding atezolizumab to cabozantinib delayed disease progression and prolonged survival in patients with disease progression on or after previous immune checkpoint inhibitor treatment.
4079. Burden of disease attributable to unsafe drinking water, sanitation, and hygiene in domestic settings: a global analysis for selected adverse health outcomes.
作者: Jennyfer Wolf.;Richard B Johnston.;Argaw Ambelu.;Benjamin F Arnold.;Robert Bain.;Michael Brauer.;Joe Brown.;Bethany A Caruso.;Thomas Clasen.;John M Colford.;Joanna Esteves Mills.;Barbara Evans.;Matthew C Freeman.;Bruce Gordon.;Gagandeep Kang.;Claudio F Lanata.;Kate O Medlicott.;Annette Prüss-Ustün.;Christopher Troeger.;Sophie Boisson.;Oliver Cumming.
来源: Lancet. 2023年401卷10393期2060-2071页
Assessments of disease burden are important to inform national, regional, and global strategies and to guide investment. We aimed to estimate the drinking water, sanitation, and hygiene (WASH)-attributable burden of disease for diarrhoea, acute respiratory infections, undernutrition, and soil-transmitted helminthiasis, using the WASH service levels used to monitor the UN Sustainable Development Goals (SDGs) as counterfactual minimum risk-exposure levels.
|